Aratana Therapeutics (NASDAQ:PETX) was upgraded by CL King to a “buy” rating in a report issued on Monday, The Fly reports. The analysts noted that the move was a valuation call.
PETX has been the subject of several other reports. Jefferies Group set a $9.00 price target on Aratana Therapeutics and gave the company a “buy” rating in a report on Thursday, November 16th. Stifel Nicolaus reissued a “hold” rating and issued a $6.00 price target on shares of Aratana Therapeutics in a report on Monday, December 18th. ValuEngine cut Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Zacks Investment Research raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, March 7th. Finally, HC Wainwright assumed coverage on Aratana Therapeutics in a report on Friday, November 17th. They issued a “buy” rating and a $10.00 price target for the company. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. Aratana Therapeutics currently has an average rating of “Hold” and an average target price of $8.55.
Aratana Therapeutics (PETX) opened at $4.26 on Monday. The company has a quick ratio of 3.08, a current ratio of 3.42 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $183.18, a P/E ratio of -2.94 and a beta of 3.13. Aratana Therapeutics has a 12 month low of $3.71 and a 12 month high of $7.67.
Hedge funds have recently modified their holdings of the stock. MetLife Investment Advisors LLC acquired a new position in Aratana Therapeutics during the fourth quarter worth $110,000. Voya Investment Management LLC raised its holdings in Aratana Therapeutics by 22.7% during the second quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 3,610 shares during the last quarter. Parametric Portfolio Associates LLC raised its holdings in Aratana Therapeutics by 6.6% during the second quarter. Parametric Portfolio Associates LLC now owns 30,127 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 1,875 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in Aratana Therapeutics by 25.3% during the second quarter. The Manufacturers Life Insurance Company now owns 34,176 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 6,898 shares during the last quarter. Finally, Ellington Management Group LLC acquired a new position in Aratana Therapeutics during the fourth quarter worth $304,000. 71.07% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://sportsperspectives.com/2018/03/12/aratana-therapeutics-petx-upgraded-at-cl-king.html.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.